June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Ranibizumab in neovascular age-related macular degeneration: an as-needed treatment regimen with bimonthly evaluation
Author Affiliations & Notes
  • Paolo Lanzetta
    Department of Medical and Biological Sciences - Ophthalmology, University of Udine, Udine, Italy
    Istituto Europeo di Microchirugia Oculare - IEMO, Udine, Italy
  • Valentina Sarao
    Department of Medical and Biological Sciences - Ophthalmology, University of Udine, Udine, Italy
  • Daniele Veritti
    Department of Medical and Biological Sciences - Ophthalmology, University of Udine, Udine, Italy
    Istituto Europeo di Microchirugia Oculare - IEMO, Udine, Italy
  • Footnotes
    Commercial Relationships Paolo Lanzetta, Alimera (C), Allergan (C), Bayer (C), Novartis (C), Roche (C); Valentina Sarao, None; Daniele Veritti, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5377. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Paolo Lanzetta, Valentina Sarao, Daniele Veritti; Ranibizumab in neovascular age-related macular degeneration: an as-needed treatment regimen with bimonthly evaluation. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5377.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Intravitreal therapies directed against vascular endothelial growth factor (VEGF) have dramatically improved the visual prognosis of choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). Debate exists regarding the best treatment and monitoring regimen for patients treated with intravitreal ranibizumab. <br /> A clinical study was conducted to evaluate the efficacy and safety of bimonthly pro-re-nata (PRN) intravitreal ranibizumab for the treatment of CNV secondary to AMD.

Methods: Thirty patients affected by CNV due to AMD received an intravitreal ranibizumab injection at baseline then PRN. Patients were scheduled for bimonthly follow-up visit examinations. Unscheduled visits and rescue injections were allowed at investigator’s discretion or based on patient-reported outcomes. As-needed and rescue treatments were performed over a 12-month follow-up period on the basis of functional or morphological criteria. The primary outcome was the average best-corrected visual acuity change at one year. Secondary outcomes were central retinal thickness changes, number of injections, number of rescue visits and treatments. Safety data were recorded.

Results: The study included 30 eyes with CNV secondary to AMD. At 12 months mean (±SD) visual acuity improvement was -0.13 (±0.23) logMAR (p<0.001) and macular thickness decreased on average by -102 (±151) µm (p<0.0001). Twenty-three percent of patients underwent a rescue visit and 13% of eyes required rescue treatment. The majority of rescue evaluations were performed at physician’s discretion. Patients received a mean of 4 injections. No significant adverse event was observed during the follow-up.

Conclusions: Pro-re-nata ranibizumab administration with bimonthly evaluations produced significant functional and morphological improvements and may be a valide choice to reduce the burden of monitoring visits and injections.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×